LOGIN  |  REGISTER
Recursion

LeMaitre Vascular to Present at Upcoming Investor Conferences in August

July 31, 2023 | Last Trade: US$92.24 0.10 0.11

BURLINGTON, Mass., July 31, 2023 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it is participating in two upcoming investor conferences in August.

JJ Pellegrino, Chief Financial Officer, will participate in the 8th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference on Monday, August 14, 2023.

David Roberts, President, will present at the UBS MedTech, Tools and Genomics Summit at the Waldorf Astoria in Dana Point, CA. The company’s presentation is scheduled at 1:00 PM PT (4:00 PM ET).

About LeMaitre

LeMaitre is a provider of devices, implants, and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures, and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. Additional information can be found at www.lemaitre.com.

Contact:
Sandra Millar
LeMaitre Vascular, Inc.
+1-781-425-1686
This email address is being protected from spambots. You need JavaScript enabled to view it.


C4 Therapeutics

Stock Quote

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB